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Abstract 
Recently, it was hypothesized that acute or cumulative suppression of non-REM sleep intensity might be related to the 
therapeutic effects of antidepressants. This intensity has been proposed to be expressed in the EEG power density in 
non-REM sleep. In the present study, the relationship was examined between the changes of EEG power density in 
non-REM sleep and the changes in clinical state in 8 depressed patients during treatment with trazodone. A l-week wash-out 
period was followed by 1 week of placebo administration, a medication period of 5 weeks and a l-week placebo period. To 
minimize systematic influences of sleep duration and non-REM-REM sleep alterations, EEG power was measured over the 
longest common amount of non-REM sleep stages 2-4 (168.5 min), accumulated from sleep onset onwards. During 
trazodone treatment, the 13-and 14-Hz bins showed a significant reduction in EEG power. No clear-cut change, however, 
was observed in the EEG power of the 6 frequency range (l-4 Hz) which is considered to be the principle manifestation of 
non-REM sleep intensity. Furthermore, no overall significant relationship between EEG power suppression and clinical 
improvement could be demonstrated. 
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1. Introduction 
The majority of antidepressant drugs (ADS) of all 
existing chemical classes suppress rapid eye move- 
ment (REM) sleep (Vogel et al., 1990; Sandor and 
Shapiro, 1994) and repeated selective REM sleep 
deprivation over 3 weeks alleviates depression. Thus, 
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ropsychology, University of Limburg, PO Box 616, 6200 MD 
Maastricht, The Netherlands. Fax: (31) (43) 685331. 
it has been hypothesized that strong initial and sus- 
tained REM sleep suppression is an important factor 
in the mechanism underlying treatment response 
(Vogel et al., 1975; Vogel et al., 1980). In studies 
with the AD amitriptyline, it was found that the 
depressive patients who improved after 5 weeks 
showed a higher degree of REM sleep suppression at 
the start of the treatment (Gillin et al., 1987; Kupfer 
et al., 1976; Kupfer et al., 1981). However, in an- 
other study clinical response after 19 days of treat- 
ment with the AD clomipramine did not correlate 
with the amount of initial REM sleep reduction 
(Riemann and Berger, 1990). In two recent studies, it 
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was found that the degree of REM sleep suppression 
during a 5-week treatment with either trazodone 
(Van Bemmel et al., 1992) or with citalopram (Van 
Bemmel et al., 1993) did not show a clear-cut rela- 
tionship with the improvement of depression either. 
Hence, REM sleep suppression may be an important 
factor in the mechanism underlying treatment re- 
sponse, but it is not sufficient. 
The reports on the effects of ADS on non-REM 
sleep are inconsistent. ADS have been reported to 
increase, decrease or not affect non-REM sleep 
(Mendelson, 1989; Nicholson et al., 1989; Sandor 
and Shapiro, 1994). It is not clear whether the effects 
on non-REM sleep are related to the improvement of 
depression. This may be due to the fact that the 
quantification of non-REM sleep changes in terms of 
changes in duration is insufficient to detect such 
relationships. BorbCly et al. (1981) have demon- 
strated in healthy subjects that the power density of 
the sleep EEG undergoes a marked, progressive de- 
crease across the sleep period. This probably reflects 
a non-REM sleep intensity dimension which remains 
largely unrecognized by visual scoring of the sleep 
EEG. 
One of the proposals pecifying the link between 
non-REM sleep and depression, the S-deficiency hy- 
pothesis, concerns this non-REM sleep intensity vari- 
able (BorbCly and Wirz-Justice, 1982; BorbCly, 
1987). According to this hypothesis the build-up of 
process S (i.e., the build-up of the pressure for 
non-REM sleep) during waking is impaired. Low 
levels of S cause depression, increased levels of S, 
e.g., by sleep deprivation, cause normalization of 
mood, while decreased levels after postdeprivation 
sleep induce deterioration of mood. The level of S is 
considered to be reflected in the EEG power density 
in non-REM sleep. Recently, it was shown in healthy 
subjects that REM sleep deprivation by arousals 
resulted in a simultaneous reduction of EEG power 
in non-REM sleep (Beersma et al., 1990). Moreover, 
Dijk et al. (1991a) have demonstrated in chipmunks 
that the administration of the AD clomipramine re- 
sulted not only in REM sleep suppression, but also in 
a decrease of non-REM sleep power in the frequen- 
cies of 1.5-13.5 Hz. These findings have led to the 
hypothesis that acute or cumulative suppression of 
non-REM sleep intensity rather than suppression of 
REM sleep is a key factor in mechanisms underlying 
improvement (Beersma and Van den Hoofdakker, 
1992). Summarizing, ADS, therefore, might be effec- 
tive because they suppress non-REM sleep intensity 
which leads to increased levels of process S. 
In the present study, we examine this possibility 
by investigating the relationships between changes in 
non-REM sleep power and changes in clinical state 
in depressive patients during treatment with the AD 
trazodone. It has been reported that trazodone does 
not suppress REM sleep in depressives whereas REM 
sleep latency and slow-wave sleep (SWS) are in- 
creased (Mouret et al., 1988; Scharf and Sachais, 
1990). Therefore, trazodone’s effects seem to ques- 
tion the significance of REM sleep suppression in 
the pharmacological lleviation of depression. In fact, 
SWS increase rather than REM sleep decrease might 
be of therapeutical significance. In an earlier report 
(Van Bemmel et al., 1992), we could not confirm 
these findings. It was shown for the patients of the 
present study that during trazodone treatment REM 
sleep decreased and REM sleep latency increased 
whereas visually scored SWS did not change signifi- 
cantly. Moreover, no clear-cut relationship could be 
shown between clinical change on the one hand and 
visually scored SWS, and REM sleep parameters on 
the other. The present report concerns an analysis of 
the relationship between changes in EEG power 
density of non-REM sleep and clinical improvement. 
2. Methods 
2.1. Study design 
Table 1 shows the main aspects of the study 
design and the dosage regimen. After a l-week 
wash-out period without medication, there were 3 
consecutive treatment periods encompassing a total 
of 7 weeks. In week 1, a placebo was administered; 
in weeks 2-6, the subjects were treated with tra- 
zodone; at the end of week 6, trazodone was abruptly 
discontinued and substituted by a placebo. The ad- 
ministration of the placebo and trazodone was sin- 
gle-blind. Subjects were informed that placebo treat- 
ment could occur. An exception to the dosage regi- 
men was made for subjects whose depression failed 
to improve after 1 week of treatment with trazodone 
at the 300 mg/day level (week 4). Their dosage was 
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Table 1 
Study design: experimental days, dosage regimen and schedule of 
sleet recordines. PLA. olacebo 








































increased to 400 mg/day (days 28-41: 13:00 200 
mg, 22:00 200 mg). 
2.2. Subjects 
The participants were 8 outpatients suffering from 
a major depression, single or recurrent [DSM-III-R 
(American Psychiatric Association, 1987) codes 
296.2 and 296.31, including insomnia (DSM-III-R 
code 307.42). In addition to this, a score of 17 or 
higher on the Hamilton rating scale for depression 
(HRSD, 17 items; Hamilton, 1967) was required. 
Subjects were only included if two psychiatrists (in- 
vestigators in the study) agreed on the diagnosis. 
Patients with other ‘axis 1’ clinical syndromes 
(according to DSM-III-R criteria) and who had re- 
ceived drugs with long half-lives (such as MAO 
inhibitors, fluoxetine, neuroleptics or long-acting 
benzodiazepines) during the 4 weeks before the start 
of the study were excluded. Subjects were free from 
psychoactive medication for at least 1 week before 
week 1 with placebo. Furthermore, subjects with a 
current history of sleep disorders uch as sleep apnea 
or nocturnal myoclonus were excluded on the basis 
of a medical interview. The results of physical exam- 
ination, ECG, blood chemistry and hematology were 
within normal limits. During the study alcohol con- 
sumption, consumption of beverages containing caf- 
feine (from lunch time), comedication and napping 
were not allowed. The compliance to the instruction 
not to nap was not controlled for by objective mea- 
surements. The protocol was reviewed and approved 
by the institutional Ethics Review Committee and 
the subjects gave informed consent. 
2.3. Measurements 
Before each sleep recording, the severity of de- 
pression of the previous week was assessed by the 
HRSD, rated by two psychiatrists. 
Sleep EEGs of each subject were recorded be- 
tween 23:00 and 07:OO at the end of each experimen- 
tal week in our sleep laboratory. The baseline night, 
recorded in the 1st week, was preceded by an adapta- 
tion night. The recordings were obtained at a paper 
speed of 10 mm/s from standard leads: 2 EOGs, 
two EEGs (C3-A2 and C4-Al) and a submental 
chin EMG. The time constants for the EOG and EEG 
recordings were 0.3 s; the high frequency cut-off was 
35 Hz. All signals were stored on magnetic tape for 
off-line analyses. 
2.4. Measures 
Depression. For each assessment, the difference 
between the two HRSD ratings obtained in each 
patient was calculated. The resulting mean (= 
-0.43) and distribution (SD = 0.78; range = 
- 1.57-1.00) of all differences, thus, calculated, in- 
dicate a close overall agreement between the two 
HRSD raters with respect o the assessment of the 
severity of depression. For every subject, the mean 
of the two HRSD ratings was used as an index of the 
severity of depression. An HRSD reduction at the 
end of the trazodone treatment (week 6) of 50% of 
the baseline score (week 1) was taken as the criterion 
for clinically significant improvement. 
Sleep recordings. These were analysed visually in 
successive 30-s epochs according to the scoring rules 
of Rechtschaffen and Kales (1968). The following 
additional variables were assessed: sleep onset: the 
first epoch, after ‘lights out’, of stages 2-4 or REM 
sleep, followed by at least 10 min of sleep, inter- 
rupted by no more than 2 min of stage 1 or wakeful- 
ness; end of sleep: the last epoch of stages 2-4 or 
REM sleep, preceded by at least 10 min of sleep, 
interrupted by no more than 2 min of stage 1 or 
wakefulness. 
In each subject, one EEG signal [obtained from 
the same lead (C3-A2 or C4-Al)] was used in the 
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analysis. It was low-pass filtered for spectral analysis 
at 25 Hz (24 dB/oct) and subsequently digitized at 
64 samples/s. Digitized data were processed by a 
fast Fourier transform routine. Power spectra were 
calculated over 4-s intervals from 0.75 to 15 Hz in 
0.25Hz bins, by applying a rectangular window. 
The 0.25~Hz bins were condensed into 1 Hz-wide 
frequency bins. Bins will be referred to by mention- 
ing their upper limit. So power density in the l-Hz 
bin is the sum of the power density of 0.75 and 1 Hz; 
power density in the ~-HZ bin is the sum of the 
power density of 1.25, 1.50, 1.75 and 2 Hz, etc. To 
obtain a resolution of 30 s, power values of 7.5 
adjacent 4-s epochs were summed for each fre- 
quency bin, thus, calculated. Visual scores of the 
same 30-s epochs were synchronized with the series 
of power spectral epochs. 
30-s epochs of non-REM sleep stages 2-4 con- 
taining EEG artefacts [mean: 5.9% (SD = 2.8) of all 
non-REM sleep 2, 3 and 4 epochs] were omitted 
from further spectral analysis, on the basis of visual 
inspection of the original tracings. The influence of 
trazodone on non-REM sleep power was analyzed on 
the basis of the longest common amount of non-REM 
sleep stages 2-4, accumulated from sleep onset on- 
wards. This approach offers the possibility to com- 
pare the EEG power production in the same amount 
of non-REM sleep in all nights (the rationale of this 
approach is explained in Discussion). 
Since the absolute values of the power densities 
of the higher frequencies are several orders of mag- 
nitude lower than those of the lower frequencies, and 
since the interindividual variation is considerable, 
absolute values are not very suitable for a visualiza- 
tion of changes in power spectra (Dijk et al., 1989). 
Therefore, in the figures power values of each sub- 
ject were expressed relative to power values in base- 
line which latter values were taken as 100%. 
2.5. Analyses 
Because of the large interindividual variability in 
the timing of the effects of trazodone on sleep and 
clinical state for each subject, the absolute EEG 
power values of the various frequency bins were 
averaged over the 5 trazodone treatment weeks. A 
one-way MANOVA for repeated measures (O’Brien 
and Kister Kaiser, 1985) was applied over the abso- 
lute power values of the baseline period, of the 
averaged trazodone treatment period and of the with- 
drawal period. The Newman-Keuls (NK) posthoc 
procedure was used to detect where significant re- 
sults were located. Spearman rank-order correlation 
( p) was used for evaluating the relationship between 
changes in depression and those in EEG power 
values. P values of < 0.05 were accepted as signifi- 
cant. 
3. Results 
Table 2 shows the clinical characteristics of the 
eight patients who participated in the study. Their 
mean HRSD score at entrance was 27.5 (SD = 3.2). 
Five subjects met the criterion of a clinically signifi- 
cant improvement and three did not. The latter three 
received the higher dosage of trazodone. 
Depression. The mean and SD values of HRSD 
scores are shown in Table 3. A one-way MANOVA 
over the baseline period, the averaged treatment 
period and the withdrawal period revealed a signifi- 
cant result in HRSD scores (F2,6 = 11.9, P = 0.01). 
The NK procedure showed that this result could be 
attributed to a significant improvement in depression 
during the trazodone treatment compared with base- 
line. There was no significant difference between 
withdrawal and treatment period. 
Sleep stages. Table 4 shows the mean values, the 
SD values and the corresponding statistics of the 
sleep stages. 
Table 2 
Age, sex (F, female; M, male), baseline HRSD scores and changes 
in HRSD scores at end of trazodone treatment period expressed 
relative to placebo-baseline values of each subject. Rank order of 
subjects is based on clinical response 
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Table 3 
Severity of depression (HRSD). Mean and SD values during 7 experimental weeks of entire patient group (n = 8). PB, placebo baseline; 
Tl-T5. 5 trazodone treatment weeks; PW. olacebo withdrawal 
PB 
.& 
Tl T2 T3 T4 T5 PW 
HRSD 26.3 20.8 14.5 16.4 15.5 11.6 16.5 
(3.5) (6.5) (8.5) (9.8) (8.3) (9.4) (8.5) 
Table 4 
Amounts in minutes between sleep onset and end of sleep of non-REM sleep stages 2, 3 and 4 (non-REM sleep); REM sleep; total time 
awake (Awake); and non-REM sleep stage 1 (Stage 1). Mean and SD values of entire patient group (n = 8) 
PB Tl T2 T3 T4 T5 PW 
non-REM sleep 256.9 288.4 309.1 
(min) l (25.4) (37.5) (26.1) 
REM sleep 76.9 49.1 43.3 
(min) l * (16.6) (27.8) (24.2) 
Awake 36.5 24.0 25.9 
(min) (25.9) (29.3) (23.1) 
Stage 1 28.4 35.4 31.4 

































PB, placebo baseline; Tl-T5, 5 trazodone treatment weeks; PW, placebo withdrawal. Significant MANOVAs over three experimental 
periods, i.e. baseline (PB), averaged trazodone treatment period (Tl-T5) and withdrawal period (PW): * F2,6 = 80.8 (P < 0.01); 
l * Fz,6 = 25.9 (P < 0.01); * * * Fz,6 = 30.6 (P(O.01). 
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Fig. 1. Mean power spectra (n = 8) of 168.5 min non-REM sleep (accumulated from sleep onset onwards) during 5 trazodone treatment 
weeks (Tl-T5) and withdrawal period (PW), relative to power spectra of baseline (PB = 100%). Power densities are plotted at upper 
bounderies of frequency bins. Frequency ranges in which power values varied significantly (P < 0.05; MANOVA) over 3 experimental 
periods, i.e., baseline (PB), averaged trazodone treatment period (Tl-TS) and withdrawal period (PW) are indicated by black bars above 
abscissa. 
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Compared with either baseline or withdrawal, un- 
der trazodone treatment, the amounts of non-REM 
sleep stages 2-4 were significantly increased and the 
amount of REM sleep decreased. By the NK proce- 
dure, the non-REM sleep stage 1 result could be 
attributed to a significant increase during the with- 
drawal period compared with both the baseline and 
the trazodone treatment period. No significant varia- 
tion over the 3 periods was found for total time 
awake. 
Power spectra in non-REM sleep. There was no 
significant relationship ( p = 0.19, P = 0.65) be- 
tween age and total EEG power in baseline (mean = 
A 





PB Tl T2 T3 T4 T5 PW 
C D 







PB Tl T2 T3 T4 T5 PW PB Tl T2 T3 T4 T5 PW 
1601.72 1.~V~/1-1.5 Hz; range = 1105.29-2718.53). 
The longest common amount of non-REM sleep 
stages 2-4, from sleep onset onwards, turned out to 
be 168.5 min. Fig. 1 shows the mean values, and the 
corresponding statistics, for the power spectra during 
the 168.5 min of non-REM sleep. 
Within these 168.5 min of non-REM sleep, 
MANOVA over the 3 experimental periods provided 
significant results for the EEG power of the l-Hz 
and 11-14-Hz bands. Although no significant change 
of EEG power was found in the lower frequency 
range during trazodone treatment, a significant de- 

















Fig. 2. Course of depressive mood (HRSD score) (A), total non-REM sleep power (l-15 Hz) (B), power in 6 band (l-4 Hz) (C) and power 
in spindle band (11-14 Hz) (D) for each subject (weekly measurements). Values are expressed relative to values of baseline period. Power 
values are obtained in 168.5 min of non-REM sleep stages 2, 3 and 4, accumulated from sleep onset onwards. Solid lines, responders; 
dashed lines, nonresponders. PB, placebo baseline; Tl-TS, 5 trazodone treatment weeks; PW, placebo withdrawal. 
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withdrawal compared with the 5-week trazodone 
treatment was noted. According to the posthoc analy- 
sis the 11-I& result could not be attributed to signifi- 
cant differences between period pairs; the 12-Hz 
result could be attributed to a significant increase in 
EEG power during withdrawal compared with the 
5-week trazodone treatment. The posthoc procedure 
further showed that the 5-week trazodone treatment 
reduced the power density of the non-REM sleep 
EEG in the 13-and 14-Hz bins. These values re- 
turned to baseline values 1 week after placebo with- 
drawal. 
Changes in EEG power in non-REM sleep and 
depression. The weekly changes in severity of de- 
pression (HRSD scores), total non-REM sleep power 
(1-15 Hz), power in the S band (l-4 Hz) and 
power in the spindle band (11-14 Hz) for each 
subject are shown in Fig. 2. 
Total power in non-REM sleep (B) and power in 
the 6 band (C) were almost similar. Therefore, as is 
frequently reported in healthy individuals, also in 
this study the total power of non-REM sleep is 
determined mainly by EEG power of the 6 band. 
On inspection, there are no clear-cut differences 
between responsers and nonresponders in the course 
of the different non-REM sleep power variables (B, 
C and D). To examine further the possible relation- 
ship between clinical change and the power vari- 
ables, the following procedure was followed. For the 
measures obtained at the end of the trazodone treat- 
ment (T5), the rank order correlations between the 
HRSD scores (expressed as deviation from the base- 
line values) and the different power values (relative 
to baseline) were calculated. Only low and nonsignif- 
icant correlations were found; total power (B): p = 
0.30 (P = 0.47); power in the S band (C): p = 0.35 
(P = 0.40); and power in the spindle band (D): 
p.= -0.35 (P = 0.40). Also no significant correla- 
tion ( p = 0.21; P = 0.62) between the amount of 
total EEG power in non-REM sleep (1-15 Hz) in 
baseline and clinical change at the end of the tra- 
zodone treatment was found. 
4. Discussion 
Before we discuss the main results of this study, 
our choice for the spectral data over the longest 
common amount of non-REM sleep as outcome vari- 
ables will be argued. The analysis of the effects of 
particular treatments on EEG power production risks 
encountering some serious pitfalls. Usually, EEG 
power is high during the first non-REM sleep episode 
and decreases during the next episodes (BorbCly et 
al., 1981; Achermann and BorbCly, 1987; Dijk et al., 
1991b). Furthermore, EEG power production waxes 
and wanes with the non-REM-REM sleep altema- 
tion, becoming very low in REM sleep. The best 
simple and direct way to compare power production 
within and between subjects is to compare the pow- 
ers produced in the longest common amount of 
non-REM sleep, accumulated from sleep onset on- 
wards (Beersma and Achermann, 1995). In this way, 
all patients have in all nights the same opportunity to 
produce power in non-REM sleep. The following 
examples may explain why this is a better variable 
than, e.g., mean EEG power over total non-REM 
sleep time. Suppose that a particular treatment does 
not have any effects on non-REM sleep power or 
sleep duration, but that it does affect intermittent 
waking or REM sleep. The mean EEG power over 
total non-REM sleep time will change then accord- 
ing to the changes in time spent in REM sleep or in 
intermittent waking. Using this variable would, thus, 
lead to the false interpretation that the treatment 
interfered with non-REM sleep power production. As 
another example, suppose that the treatment pro- 
duces a change in sleep duration. Since EEG power 
is usually low at the end of sleep, longer sleep will 
lead to a lower mean EEG power, even if power 
production is not affected by the treatment. Again, 
reliance on this variable would result in a false 
interpretation of the real effects of the intervention. 
In an attempt to avoid the aforementioned prob- 
lem, some authors (Reynolds et al., 1991) have 
chosen to use the power production in the first 
non-REM-REM sleep cycle as a critical variable. 
However, this leads to another problem. In the course 
of a non-REM sleep episode, EEG power increases 
until it reaches a plateau value, followed by a rather 
steep decline shortly before REM sleep (Achermann 
and BorbCly, 1990). If a treatment merely lengthens 
REM sleep latency, the EEG power plateau will last 
longer and the mean level of EEG power will in- 
crease. Mean EEG power production would then 
erroneously suggest that the treatment interferes di- 
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rectly with non-REM sleep power production per se. 
Similar remarks can be made with respect to the 
study of Kupfer et al. (1989). In this study, non-REM 
sleep power during the first 100 min of baseline 
sleep was compared with power during the same 
interval of sleep after a ‘loading dose’ of 
clomipramine. However, the duration of REM sleep 
and wakefulness within the lOO-min intervals may 
be expected to have been very different under the 
two conditions. No data regarding these critical is- 
sues are provided by the authors. 
Although in our study changes in power produc- 
tion are controlled for changes in sleep duration and 
in the distribution and duration of REM sleep peri- 
ods, some interpretation problems remain. Also the 
frequency of sleep interruptions i of influence upon 
non-REM sleep power. An interruption leads to re- 
duced power values, followed by a relaxation period 
in which power gradually increases again. It cannot 
be excluded that changes in sleep continuity have 
influenced the power spectra. Knowledge of the 
dynamics of these processes is not yet sufficient to 
estimate the consequences of these effects (Acher- 
mann and BorbCly, 1987). Nevertheless, the absence 
of significant variations over the experimental peri- 
ods in total intermittent wakefulness and over the 
treatment weeks in stage 1 sleep suggests that it is 
reasonable to assume that changes in sleep continuity 
were of little influence for the results of our analysis. 
Our analysis resulted in the finding that during 
trazodone treatment the EEG power of the 13-and 
14-Hz bins during non-REM sleep was significantly 
suppressed in the entire patient group. No significant 
change was found, however, for the EEG power 
values of the 6 frequency range (l-4 Hz) which is 
considered to be the principle manifestation of non- 
REM sleep intensity. Furthermore, no clear-cut rela- 
tionship between clinical change and changes in 
non-REM sleep power density could be demon- 
strated. However, because the three nonresponders 
received the higher dosage of trazodone (400 mg/ 
day), it cannot be excluded that a different dosage of 
trazodone affects the EEG power spectra differently, 
irrespective of clinical change. 
The influence of trazodone on the power density 
in the 13-14-Hz range in the entire patient group 
seems to be opposite to the influence of hypnotics. 
All studied benzodiazepines and nonbenzodiazepine 
hypnotics are reported to increase this activity 
(BorbCly et al., 1991). This increase appeared to be 
closely related to the sleep-promoting action. Be- 
cause no clear change in sleep continuity and subjec- 
tive sleep quality could be observed (Van Bemmel et 
al., 19921, the opposite statement does not seem to 
hold. The N 40% reduction in 13-14-Hz activity 
due to trazodone did not lead to changes in sleep 
continuity and quality. Since the (patho)physiologi- 
cal significance of changes in activity in this fre- 
quency range are yet unknown (Hirshkowitz et al., 
1982; BorbCly et al., 19911, the interpretation of our 
results must await further research in this field. 
In summary, both our previous analysis (Van 
Bemmel et al., 1992) and the present analysis did not 
provide clear evidence of involvement of non-REM 
sleep intensity in the mechanisms underlying clinical 
change during trazodone treatment. However, it 
should be noted that caution is warranted because of 
the small number of subjects. Moreover, it should be 
kept in mind that the results are based on compar- 
isons with just one baseline sleep recording. 
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